Skip to main content
  1. Market Insights
  2. Health
  3. Pharmaceuticals
  4. Vaccines

COVID-19 Vaccines - Guatemala

Guatemala
  • In Guatemala, the revenue in the COVID-19 Vaccines market is forecasted to reach US$46.95m by 2024.
  • It is expected to exhibit a compound annual growth rate (CAGR 2024-2029) of -17.35%, leading to a market volume of US$18.10m by 2029.
  • When compared globally, United States is projected to generate the highest revenue of US$4.39bn in 2024.
  • Guatemala is experiencing a surge in demand for COVID-19 vaccines as the government ramps up its vaccination campaign to reach remote areas.

Definition:
This market covers vaccines against COVID-19. Included are different types of vaccines (mRNA-based, viral vector vaccines).

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Pfizer, Moderna, Biontech, Johnson & Johnson, AstraZeneca

In-Scope

  • COVID-19 vaccines
  • mRNA-based vaccines
  • Viral vector vaccines

Out-Of-Scope

  • Vaccines against other diseases
  • Antivirals
Pharmaceuticals: market data & analysis - Cover

Market Insights report

Pharmaceuticals: market data & analysis

Study Details

    Revenue

    Notes: Data shown is using current exchange rates and reflects market impacts of the Russia-Ukraine war.

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Notes: The chart “Comparable Estimates” shows the forecasted development of the selected market from different sources. Please see the additional information for methodology and publication date.

    Most recent update: Mar 2024

    Analyst Opinion

    Guatemala, a country located in Central America, has been significantly affected by the COVID-19 pandemic. As the world races to develop and distribute vaccines, the COVID-19 vaccines market in Guatemala is also experiencing several trends and developments.

    Customer preferences:
    The Guatemalan population has shown a willingness to receive the COVID-19 vaccine. However, there is a significant disparity in vaccine access between urban and rural areas. While the urban population has better access to vaccines, the rural population faces challenges such as transportation and lack of information on vaccine availability.

    Trends in the market:
    One of the significant trends in the COVID-19 vaccines market in Guatemala is the increasing availability of vaccines. The government has been actively working to secure vaccines from various sources, including the COVAX facility. Additionally, private companies are also importing vaccines to meet the demand.Another trend is the emergence of vaccine tourism. Wealthy individuals from neighboring countries are traveling to Guatemala to receive the vaccine. This trend has led to concerns about vaccine equity and the potential for the spread of new COVID-19 variants.

    Local special circumstances:
    Guatemala has a high poverty rate, and the pandemic has exacerbated this situation. The government has been providing financial assistance to vulnerable populations to mitigate the economic impact of the pandemic. However, the availability of vaccines is still limited, and the government is facing challenges in distributing vaccines to remote areas.

    Underlying macroeconomic factors:
    The COVID-19 pandemic has had a significant impact on the Guatemalan economy. The country's GDP contracted by 1.5% in 2020, and the unemployment rate has increased. The government has been implementing measures to support businesses and workers, but the economic recovery is expected to be slow.In conclusion, the COVID-19 vaccines market in Guatemala is experiencing several trends and developments, including increasing vaccine availability and the emergence of vaccine tourism. However, the government is facing challenges in distributing vaccines to remote areas, and concerns about vaccine equity persist. The underlying macroeconomic factors, such as the impact of the pandemic on the economy, are also affecting the market.

    Global Comparison

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Methodology

    Data coverage:

    Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

    Modeling approach / Market size:

    Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

    Forecasts:

    In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

    Additional notes:

    Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

    Health

    Access more Market Insights on Health topics with our featured report

    Pharmaceuticals: market data & analysis - BackgroundPharmaceuticals: market data & analysis - Cover

    Key Market Indicators

    Notes: Based on data from IMF, World Bank, UN and Eurostat

    Most recent update: Sep 2024

    Source: Statista Market Insights

    Explore more high-quality data on related topic

    Coronavirus (COVID-19): vaccines and vaccination campaign

    As of March 2023, more than 13 billion COVID-19 vaccine doses had been administered worldwide. Wide-spread vaccine availability, increasing herd immunity, and lower case numbers led to renewed hope and a feeling of normality in 2023. However, especially during the winter seasons and with the potential emergence of new variants of the virus (like Omicron in 2021-2022), tracking of coronavirus cases repeatedly becomes a focus for the public. Thus, there is a level of uncertainty about what developments the winter season 2023/2024 might bring.
    More data on the topic

    Contact

    Get in touch with us. We are happy to help.